AlphaQuest LLC Purchases 7,818 Shares of Twist Bioscience Co. (NASDAQ:TWST)

AlphaQuest LLC grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 216.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,422 shares of the company's stock after purchasing an additional 7,818 shares during the period. AlphaQuest LLC's holdings in Twist Bioscience were worth $531,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Van ECK Associates Corp boosted its position in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience in the third quarter worth approximately $34,000. US Bancorp DE raised its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after acquiring an additional 601 shares in the last quarter. Beaird Harris Wealth Management LLC bought a new position in Twist Bioscience during the third quarter valued at approximately $95,000. Finally, KBC Group NV lifted its stake in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after acquiring an additional 1,226 shares during the last quarter.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 2,402 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $98,265.82. Following the completion of the transaction, the chief executive officer now directly owns 662,692 shares of the company's stock, valued at $27,110,729.72. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dennis Cho sold 806 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the sale, the insider now directly owns 112,221 shares in the company, valued at $5,538,106.35. This trade represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,845 shares of company stock worth $1,603,945. Company insiders own 3.01% of the company's stock.

Remove Ads

Twist Bioscience Stock Performance

Shares of TWST stock traded down $0.20 during trading hours on Thursday, reaching $39.12. 1,013,302 shares of the company's stock were exchanged, compared to its average volume of 1,005,365. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.33 billion, a P/E ratio of -11.57 and a beta of 2.15. The business has a fifty day moving average price of $46.04 and a 200-day moving average price of $45.35.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the firm earned ($0.75) EPS. The business's revenue was up 24.1% on a year-over-year basis. Analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TWST shares. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. TD Cowen reiterated a "buy" rating and set a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Finally, Barclays set a $58.00 target price on Twist Bioscience and gave the stock an "overweight" rating in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $54.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.